News
Updated and committed to information
LONG-TERM SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED ADVANCED OVARIAN CANCER AND BRCA MUTATIONS TREATED WITH OLAPARIB
In this double-blind phase III clinical trial, patients with newly diagnosed ovarian cancer and a BRCA mutation (germline or somatic) who responded to platinum-based chemotherapy
SEOM UPDATES ON DIAGNOSTIC AND THERAPEUTIC ADVANCES IN SARCOMAS
Sarcomas have undergone important advances in their diagnosis and treatment in recent years. For this reason, coinciding with Sarcoma Day in Spain, which is celebrated
NEW DRUG SCREENING METHOD FOR THE TREATMENT OF BRAIN METASTASES
The incidence of brain metastases continues to increase, currently affecting 25% of cancer patients. But currently available therapies have limited efficacy and fail to improve
PROGNOSTIC IMPACT OF NPM1 AND FLT3 MUTATIONS IN PATIENTS WITH LMA IN FIRST REMISSION RECEIVING ORAL AZACITIDINE MAINTENANCE.
The trial conducted by Hartmut Döhner and his research group has shown that, compared to placebo, oral azacitidine improved overall survival in patients with acute
ctDNA to Guide Panitumumab Rechallenge in Metastatic Colorectal Cancer
Monoclonal antibodies against epidermal growth factor receptor (EGFR) are approved for the treatment of metastatic RAS-like colorectal cancer (WT), but the emergence of resistance mutations
TABRECTA GAINS FULL FDA APPROVAL FOR NON-SMALL CELL LUNG CANCER
The U.S. Food and Drug Administration (FDA) has approved the drug capmatinib (Tabrecta) for adult patients with metastatic non-small cell lung cancer (NSCLC), whose tumors
